Table 1 Demographic information of study participants

Mean age

11.2 years (SD = 3.9 years)

Mean duration of Methotrexate therapy

2.5 years (SD = 2.1 years)

Sex

Female:

28/41

68%

Rheumatologic diagnosis*

JIA:

30/41

73%

Uveitis:

14/41

34%

Scleroderma:

10/41

24%

Dermato/Polymyositis:

2/41

5%

SLE

1/41

2%

Other

4/41

10%

Number of active joints at time of interview

0 Active Joints:

34/41

82%

1 Active Joint:

5/41

12%

2 Active Joints:

1/41

2%

3 Active Joints:

1/41

2%

Non-Methotrexate rheumatologic medications

None:

15/41

37%

Biologics:

15/41

37%

Prednisone:

11/41

27%

NSAID:

5/41

12%

Methylprednisolone:

2/41

5%

Other (i.e. topical):

8/41

20%

Folic acid

1 mg daily or 5 mg weekly

29/41

71%

None

12/41

29%